Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
Aclaris Therapeutics (NASDAQ: ACRS) announced promising preliminary topline data for ATI-450, an oral MK2 inhibitor, from its Phase 2a trial in moderate to severe rheumatoid arthritis. This investigational drug showed significant clinical activity with sustained reductions in DAS28-CRP scores and enhanced inflammatory biomarker suppression over 12 weeks. For Q4 2020, Aclaris reported a net loss of $13.2 million, a decrease from $18.6 million in Q4 2019, along with total revenues of $1.6 million. Following a public offering in January 2021, Aclaris secured $103.5 million to strengthen its balance sheet.
- Positive preliminary data for ATI-450 shows sustained clinical activity in rheumatoid arthritis.
- Successfully raised $103.5 million in a public offering to enhance liquidity.
- Net loss of $51.0 million for 2020 compared to $161.4 million in 2019 indicates continued financial challenges.
- Total revenue for 2020 at $6.5 million is relatively low compared to operational costs.
- Positive Preliminary Topline Data for ATI-450, an Investigational Oral MK2 Inhibitor, in Moderate to Severe Rheumatoid Arthritis Announced in January 2021
- ATI-450 Data Support New Oral Approach for the Potential Treatment of Immuno-inflammatory Diseases, such as Rheumatoid Arthritis
- Public Offering of
$103.5M in January 2021 Strengthens Balance Sheet
WAYNE, Pa., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year of 2020 and provided a corporate update.
“As we reflect on 2020, we are proud of how we have progressed our immuno-inflammatory development programs,” said Dr. Neal Walker, President & CEO of Aclaris. “We are very excited about the platform potential of ATI-450, an oral MK2 inhibitor which we have shown to inhibit TNFα, IL1β, and IL6. Given its novel mechanism, there are several immuno-inflammatory indications that ATI-450 may potentially address. We are also excited about the potential of our pipeline which is internally generated from KINect®, our proprietary drug discovery platform, for various immuno-inflammatory indications. We look forward to building on this momentum in 2021.”
Research and Development Highlights:
The global COVID-19 pandemic continues to rapidly evolve and has caused and may continue to cause Aclaris to experience disruptions that could impact the timing of its research and development and regulatory activities listed below.
- ATI-450, an investigational oral small molecule MK2 inhibitor compound:
- ATI-450-RA-201: A Phase 2a, multicenter, randomized, investigator and patient-blind, sponsor-unblinded, parallel group, placebo-controlled clinical trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of ATI-450 in subjects with moderate to severe rheumatoid arthritis.
- Positive preliminary topline data announced in January 2021. In this trial, ATI-450 demonstrated durable clinical activity, as defined by a marked and sustained reduction in DAS28-CRP and improvement of ACR20/50/70 responses over 12 weeks. This clinical activity was further supported by pharmacodynamic analyses showing a marked and durable inhibition of TNFα, IL1β, IL6, and IL8 in ex vivo stimulated samples as well as an endogenous inflammation biomarker analysis which also demonstrated a marked and sustained inhibition of median concentrations of hsCRP, TNFα, IL6, IL8, and MIP1β in the treatment arm over the 12 week period.
- ATI-450 was generally well tolerated. The most common adverse events (AE) (each reported in 2 subjects) were urinary tract infection (UTI), elevated lipids and ventricular extrasystoles, all of which were determined to be unrelated to treatment except for one UTI. There was one non-treatment-related serious adverse event (COVID-19) reported in the four-week safety follow-up phase of the trial in a subject who was no longer receiving treatment.
- Aclaris intends to progress ATI-450 into a Phase 2b trial in moderate to severe rheumatoid arthritis in the second half of 2021.
- Aclaris is currently evaluating additional potential indications driven by TNFα, IL1β and IL6 as part of its planned expansion of its Phase 2 immuno-inflammatory clinical development programs.
- ATI-450-PKPD-102: A Phase 1, placebo-controlled, randomized, observer-blind clinical trial to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ATI-450 at 80 mg and 120mg twice daily in health subjects.
- Positive preliminary topline data announced in January 2021. Pharmacodynamic analysis demonstrated incremental cytokine suppression at these higher doses. ATI-450 was generally well tolerated. The most common AEs (reported by 2 or more subjects who received ATI-450) were headache, dizziness, nausea, parasthesia and, in the post-dosing safety follow-up phase of the trial, dry skin. These AEs were all mild in severity.
- A final analysis of this trial is underway.
- ATI-450-CAPS-201: A Phase 2a, multicenter, open-label, single-arm clinical trial to investigate the safety, tolerability, efficacy and pharmacodynamics of ATI-450 for the maintenance of remission in subjects with cryopyrin-associated periodic syndrome (CAPS) previously managed with anti-IL1 therapy. Due to the COVID-19 pandemic, subject enrollment in this trial was paused. As a result of the ongoing pandemic and given the positive preliminary topline data from the ATI-450-RA-201 trial, Aclaris has decided to focus its efforts and resources on other immuno-inflammatory diseases.
- ATI-450-RA-201: A Phase 2a, multicenter, randomized, investigator and patient-blind, sponsor-unblinded, parallel group, placebo-controlled clinical trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of ATI-450 in subjects with moderate to severe rheumatoid arthritis.
- ATI-1777, an investigational topical “soft” Janus Kinase (JAK) 1/3 inhibitor compound:
- ATI-1777-AD-201: An ongoing Phase 2a, multicenter, randomized, double-blind, vehicle-controlled, parallel-group clinical trial to investigate the efficacy, safety, tolerability and pharmacokinetics of ATI-1777 in subjects with moderate to severe atopic dermatitis. The primary endpoint is the percentage change from baseline in the Eczema Area and Severity Index (EASI) score at week 4. Data from this trial are expected mid-year 2021.
- ATI-2138, an investigational oral ITK/TXK/JAK3 (ITJ) inhibitor compound:
- Aclaris is developing ATI-2138 as a potential treatment for T-cell mediated diseases such as psoriasis and/or inflammatory bowel disease and expects to submit an Investigational New Drug Application for ATI-2138 in the second half of 2021.
Financial Highlights:
Liquidity and Capital Resources
As of December 31, 2020, Aclaris had aggregate cash, cash equivalents, restricted cash and marketable securities of
- Net cash used in operating activities was
$38.6 million resulting from net loss of$51.0 million and changes in operating assets and liabilities of$2.4 million , partially offset by non-cash adjustments of$14.7 million . - Net borrowings of
$10.9 million pursuant to a Loan and Security Agreement. - Net proceeds of
$7.7 million from the sale of 2.1 million shares of common stock under an equity line of credit agreement.
In January 2021, Aclaris closed a public offering in which it sold approximately 6.3 million shares of common stock. Proceeds from the offering were
Financial Results
Fourth Quarter 2020
- Net loss was
$13.2 million for the fourth quarter of 2020 compared to$18.6 million for the fourth quarter of 2019. Loss from continuing operations was$13.6 million for the quarter ended December 31, 2020 compared to$19.2 million for the prior year period.
- Total revenue was
$1.6 million for the fourth quarter of 2020 compared to$1.1 million for the fourth quarter of 2019. - Research and development (R&D) expenses were
$9.0 million for the quarter ended December 31, 2020 compared to$11.5 million for the prior year period.
- The quarter-over-quarter decrease of
$2.6 million was primarily the result of expenses related to Aclaris’ legacy JAK inhibitors ATI-501 and ATI-502, including the substantial completion of Aclaris’ various Phase 2 clinical trials, and the substantial completion of two pivotal Phase 3 clinical trials of A-10145% Topical Solution in 2019.
- The quarter-over-quarter decrease of
- General and administrative (G&A) expenses were
$4.9 million for the quarter ended December 31, 2020 compared to$5.8 million for the prior year period.
- The quarter-over-quarter decrease of
$0.9 million was primarily the result of lower non-cash stock-based compensation expense resulting from headcount reductions. Stock-based compensation expense was$1.6 million compared to$2.6 million in the prior year period.
- The quarter-over-quarter decrease of
Full Year 2020
- Net loss was
$51.0 million for the year ended December 31, 2020 compared to$161.4 million for the year ended December 31, 2019. Loss from continuing operations was$51.2 million for the year ended December 31, 2020 compared to$113.5 million for the prior year period. Income from discontinued operations was$0.1 million for the year ended December 31, 2020 compared to a loss from discontinued operations of$47.8 million for the year ended December 31, 2019. - Total revenue was
$6.5 million for the year ended December 31, 2020 compared to$4.2 million for the year ended December 31, 2019. - R&D expenses were
$31.7 million for the year ended December 31, 2020 compared to$64.9 million for the prior year period.
- The decrease of
$33.2 million was primarily the result of expenses related to ATI-501 and ATI-502, including the substantial completion of Aclaris’ various Phase 2 clinical trials, and the substantial completion of two pivotal Phase 3 clinical trials of A-10145% Topical Solution in 2019. - R&D expenses in 2020 included non-cash stock-based compensation expense of
$2.9 million compared to$5.1 million in the prior year period.
- The decrease of
- G&A expenses were
$20.5 million for the year ended December 31, 2020 compared to$27.8 million for the prior year period.
- The decrease of
$7.3 million was primarily the result of lower personnel and non-cash stock-based compensation resulting from headcount reductions. - G&A expenses in 2020 included non-cash stock-based compensation expense of
$7.3 million compared to$10.3 million in the prior year period.
- The decrease of
- For the year ended December 31, 2019, there was also a
$18.5 million non-cash charge for the impairment of goodwill.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Aclaris’ current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of Aclaris’ drug candidates, including the availability of data from its clinical trials and timing for regulatory filings, and its belief that its existing cash, cash equivalents and marketable securities will be sufficient to fund its operations through the end of 2023. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Aclaris’ reliance on third parties over which it may not always have full control, Aclaris’ ability to enter into strategic partnerships on commercially reasonable terms, the uncertainty regarding the COVID-19 pandemic and other risks and uncertainties that are described in the Risk Factors section of Aclaris’ Annual Report on Form 10-K for the year ended December 31, 2020, and other filings Aclaris makes with the U.S. Securities and Exchange Commission from time to time. These documents are available under the “SEC Filings” page of the “Investors” section of Aclaris’ website at www.aclaristx.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to Aclaris as of the date of this release, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
Aclaris Therapeutics, Inc.
Consolidated Statements of Operations
(unaudited, in thousands, except share and per share data)
| Three Months Ended | Year Ended | ||||||||||||||
| December 31, | December 31, | ||||||||||||||
| 2020 | 2019 | 2020 | 2019 | ||||||||||||
| Revenues: | |||||||||||||||
| Contract research | $ | 1,413 | $ | 1,095 | $ | 5,786 | $ | 4,227 | |||||||
| Other revenue | 167 | — | 696 | — | |||||||||||
| Total revenue | 1,580 | 1,095 | 6,482 | 4,227 | |||||||||||
| Costs and expenses: | |||||||||||||||
| Cost of revenue (1) | 1,286 | 1,028 | 5,133 | 4,055 | |||||||||||
| Research and development (1) | 8,956 | 11,540 | 31,731 | 64,899 | |||||||||||
| General and administrative (1) | 4,898 | 5,809 | 20,530 | 27,827 | |||||||||||
| Goodwill impairment | — | — | — | 18,504 | |||||||||||
| Total costs and expenses | 15,140 | 18,377 | 57,394 | 115,285 | |||||||||||
| Loss from operations | (13,560 | ) | (17,282 | ) | (50,912 | ) | (111,058 | ) | |||||||
| Other expense, net | (219 | ) | (1,895 | ) | (424 | ) | (2,484 | ) | |||||||
| Loss from continuing operations before income taxes | (13,779 | ) | (19,177 | ) | (51,336 | ) | (113,542 | ) | |||||||
| Income tax benefit | (182 | ) | — | (182 | ) | — | |||||||||
| Loss from continuing operations | (13,597 | ) | (19,177 | ) | (51,154 | ) | (113,542 | ) | |||||||
| Income (loss) from discontinued operations, net of tax (1) | 424 | 583 | 139 | (47,812 | ) | ||||||||||
| Net loss | $ | (13,173 | ) | $ | (18,594 | ) | $ | (51,015 | ) | $ | (161,354 | ) | |||
| Net loss per share, basic and diluted | $ | (0.30 | ) | $ | (0.45 | ) | $ | (1.20 | ) | $ | (3.90 | ) | |||
| Weighted average common shares outstanding, basic and diluted | 43,588,095 | 41,405,657 | 42,539,293 | 41,323,921 | |||||||||||
| (1) Amounts include stock-based compensation expense as follows: | |||||||||||||||
| Cost of revenue | $ | 218 | $ | 249 | $ | 946 | $ | 703 | |||||||
| Research and development | 727 | 358 | 2,919 | 5,091 | |||||||||||
| General and administrative | 1,559 | 2,581 | 7,342 | 10,288 | |||||||||||
| Income (loss) from discontinued operations, net of tax | — | (7 | ) | — | 95 | ||||||||||
| Total stock-based compensation expense | $ | 2,504 | $ | 3,181 | $ | 11,207 | $ | 16,177 | |||||||
Aclaris Therapeutics, Inc.
Selected Consolidated Balance Sheet Data
(unaudited, in thousands)
| December 31, 2020 | December 31, 2019 | ||||||
| Cash, cash equivalents, restricted cash and marketable securities | $ | 54,131 | $ | 75,015 | |||
| Total assets | 70,784 | 98,297 | |||||
| Total current liabilities | 14,874 | 22,432 | |||||
| Total liabilities | 33,134 | 28,385 | |||||
| Total stockholders' equity | 37,650 | 69,912 | |||||
Aclaris Contact
FAQ
What are the preliminary data results for ATI-450 reported by Aclaris?
How much did Aclaris raise in their January 2021 public offering?
What were Aclaris' financial results for Q4 2020?
What is the outlook for Aclaris after the January 2021 funding?
